NCT05025241 - An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

November 1, 2023

Study Completion Date

November 17, 2023

Conditions

Phelan-McDermid Syndrome

Interventions

DRUG

NNZ-2591

NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.

Trial Locations (4)

Rush University Medical Center, Chicago

Texas Children's Hospital, Houston

Massachusetts General Hospital, Boston

Boston Children's Hospital, Boston